U.S. markets closed

Autolus Therapeutics plc (AUTL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.61-0.97 (-9.17%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close10.58
Open10.59
Bid9.39 x 1400
Ask10.00 x 2200
Day's Range9.13 - 10.59
52 Week Range3.00 - 17.19
Volume154,116
Avg. Volume71,250
Market Cap502.592M
Beta (5Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-1.40
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference
    GlobeNewswire

    Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference

    LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference: * 19 November 2020 – Dr. Christian Itin, chairman and chief executive officer, will participate in an analyst led fireside chat and host virtual one-on-one meetings at the Jefferies Virtual London Healthcare Conference at 11.25 pm ET, 4.25 pm GMT. A live audio webcast of the fireside chat will be available on the investor relations section of the Company’s website at Autolus. An archived replay will be available for a period of 30 days after the conference. * 7 December 2020 – Dr. Christian Itin, chairman and chief executive officer, along with the Autolus clinical team, will host an investor call and webcast at 4.00 pm ET, 9.00 pm GMT to discuss presentations related to its AUTO1 and AUTO3 programs, the company’s CAR T cell therapies being investigated in adult Acute Lymphoblastic Leukemia (ALL) and relapsed/ refractory diffuse large B cell lymphoma (DLBCL), respectively, during the ASH conference. To listen to the webcast and view the accompanying slide presentation, please go to Autolus. After the conference call, a replay will be available for a period of one week. About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.Contact: Lucinda Crabtree, PhD Vice President, Investor Relations and Corporate Communications +44 (0) 7587 372 619  l.crabtree@autolus.comJulia Wilson +44 (0) 7818 430877 j.wilson@autolus.comSusan A. Noonan S.A. Noonan Communications +1-212-966-3650 susan@sanoonan.com

  • Earnings Beat: Autolus Therapeutics plc (NASDAQ:AUTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
    Simply Wall St.

    Earnings Beat: Autolus Therapeutics plc (NASDAQ:AUTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

    The third-quarter results for Autolus Therapeutics plc (NASDAQ:AUTL) were released last week, making it a good time to...

  • News Flash: Analysts Just Made A Meaningful Upgrade To Their Autolus Therapeutics plc (NASDAQ:AUTL) Forecasts
    Simply Wall St.

    News Flash: Analysts Just Made A Meaningful Upgrade To Their Autolus Therapeutics plc (NASDAQ:AUTL) Forecasts

    Shareholders in Autolus Therapeutics plc (NASDAQ:AUTL) may be thrilled to learn that the analysts have just delivered...